Blood test predicts chemotherapy resistance in prostate cancer
11th November 2021
Research conducted at Barts Cancer Institute (BCI), Queen Mary University of London, indicates that regular blood tests before and during chemotherapy for prostate cancer can detect whether or not a patient is resistant or developing resistance to treatment with a drug called docetaxel. Ms Caitlin Davies, a PhD student at BCI, presented the findings from her PhD research at the National Cancer Research Institute (NCRI) Festival, which is taking place from 8-12th November 2021.
Read more
AI algorithm identifies most effective drugs for liver cancer
1st November 2021
Researchers from Barts Cancer Institute at Queen Mary University of London and King’s College Hospital have shown that a new computer-based algorithm can rank drugs used to treat primary liver cancer, based on their efficacy in reducing cancer cell growth.
Read more
Overcoming drug resistance in breast cancer
28th October 2021
In recognition of Breast Cancer Awareness Month, we spoke with Dr Ioanna Keklikoglou, Lecturer and Group Leader in the Centre for Tumour Microenvironment at Barts Cancer Institute, Queen Mary University of London. Dr Keklikoglou’s research focuses on understanding the molecular and cellular mechanisms that control resistance to anti-cancer therapies in breast cancer.
Read more
BCI research features in new Science Museum Group exhibition on cancer
25th October 2021
A research project led by Professor Fran Balkwill from Barts Cancer Institute at Queen Mary University of London features in a world-first free exhibition exploring the revolution in science that is transforming cancer care.
Read more
Celebrating the work of our PhD students
15th October 2021
On 28th September, we held our annual PhD Day – an event that celebrates the work of the postgraduate research students at the Barts Cancer Institute, Queen Mary University of London.
Read more
OPTIMA: Improving treatment for cancer patients through artificial intelligence
12th October 2021
Professors Claude Chelala and Louise Jones from Barts Cancer Institute, Queen Mary University of London, are part of a €21.3 million public-private research programme that will seek to use artificial intelligence to improve care for patients with prostate, breast and lung cancer.
Read more